Welcome to our dedicated page for Sarepta Therapeutics news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) granted equity awards on June 30, 2026 under its 2024 Employment Commencement Incentive Plan as material inducements for 30 second-quarter hires. The awards total 151,305 restricted stock units (RSUs), approved in accordance with Nasdaq Listing Rule 5635(c)(4).
RSUs vest over four years, with one-fourth vesting annually on each grant-date anniversary, subject to continued employment. No stock options were granted.
Sarepta Therapeutics (NASDAQ:SRPT) announced that the FDA has accepted for review supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 to convert their accelerated approvals in Duchenne muscular dystrophy to traditional approvals. The FDA set a PDUFA target action date of February 28, 2027.
The filings are supported by Phase 3 ESSENCE data, extensive real-world evidence in over 1,800 treated patients, and established safety profiles. In ESSENCE, the primary endpoint was not met, though numerical trends favored treatment and week‑96 data showed increased dystrophin and functional preservation.
Sarepta Therapeutics (NASDAQ:SRPT) announced participation in two June 2026 investor events in Miami Beach. Senior management will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 and hold investor meetings at the Oppenheimer CNS and Neuro-Muscular Summit on June 10.
The Goldman Sachs fireside chat will be webcast live and archived for 90 days in the investor relations section of Sarepta’s website. Sarepta highlights its focus on precision genetic medicine for rare diseases and encourages investors to check the “For Investors” section of its website for updates.
Sarepta Therapeutics (NASDAQ:SRPT) announced that senior management will take part in a fireside chat at the RBC Capital Markets Global Healthcare Conference at the InterContinental New York Barclay on Wednesday, May 20, at 8:30 a.m. ET.
The presentation will be webcast live and archived for 90 days on Sarepta’s investor relations website.
Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 2026 results with total revenues of $730.8 million and net product revenues of $330.5 million (ELEVIDYS $102.0M; PMO $228.6M). GAAP operating income was $358.4 million. Cash and investments totaled $748.3 million as of March 31, 2026. Clinical and regulatory progress included early Phase 1/2 siRNA data for SRP-1001 and SRP-1003, ENDEAVOR Cohort 8 dosing underway, and sNDA submissions for AMONDYS 45 and VYONDYS 53.
Company reiterated FY2026 revenue guidance of $1.2–$1.4 billion and combined non-GAAP R&D and SG&A guidance of $800–$900 million.
Sarepta Therapeutics (NASDAQ:SRPT) will report first quarter 2026 financial results after the Nasdaq close on Wednesday, May 6, 2026. A conference call and live webcast will follow at 4:30 p.m. ET, with a replay archived for one year.
Phone participants must register online to receive dial-in details and a personal PIN. Investors are encouraged to consult the company's investor relations site for related filings and materials.
Sarepta Therapeutics (NASDAQ:SRPT) granted inducement equity awards on March 31, 2026 to 24 employees hired in Q1 2026 under the company’s 2024 Employment Commencement Incentive Plan. The awards total 113,855 restricted stock units (RSUs) and vest 25% annually over four years, subject to continued employment. Awards were approved pursuant to Nasdaq Listing Rule 5635(c)(4). No stock options were granted.
Sarepta (NASDAQ:SRPT) reported first clinical data from Phase 1/2 studies of two αvβ6 integrin-targeted siRNA candidates, SRP-1001 (FSHD1) and SRP-1003 (DM1).
Early results show dose-dependent muscle and plasma exposures, single-dose target knockdown, and favorable tolerability with no dose-limiting toxicities reported to date. An investor webcast is scheduled March 25, 2026.
Sarepta (NASDAQ:SRPT) will present early clinical results from Phase 1/2 ascending‑dose studies of SRP‑1001 (FSHD1) and SRP‑1003 (DM1) on March 25, 2026 at 8:30 AM ET via live webcast and conference call.
Replay will be archived on the investor relations site for one year; phone participants must register to receive dial‑in and PIN details.
Sarepta (NASDAQ:SRPT) will submit supplemental NDAs by the end of April 2026 seeking conversion of AMONDYS 45 and VYONDYS 53 accelerated approvals to traditional approvals.
ESSENCE topline showed non‑significant primary results (LSM difference 0.06 steps/sec, P=0.309); an updated COVID‑adjusted analysis reached P=0.050. No new safety signals; company will include ESSENCE and real‑world evidence in the sNDAs.